UBS Adjusts Stryker Price Target to $400 From $386, Maintains Neutral Rating

robot
Abstract generation in progress

UBS has increased its price target for Stryker (SYK) to $400 from $386, while reiterating a Neutral rating on the stock. This adjustment comes as Stryker, a leading medical equipment manufacturer, continues to operate in the medical surgery, neurotechnology, and orthopaedics sectors. The company recently launched new products, including Synchfix?? EVT and the T2 Alpha Humerus Nailing System.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin